Content-Transfer-Encoding: |
7bit |
Sender: |
|
Subject: |
|
From: |
|
Date: |
Sun, 27 Jun 2004 12:14:00 EDT |
Content-Type: |
text/plain; charset="US-ASCII" |
MIME-Version: |
1.0 |
Reply-To: |
|
Parts/Attachments: |
|
|
Janie reports:
**************************************************
Tom Hale questions efficacy of
domperidone and says that there is no mechanism by which it should work.
This leaves us with a drug of questionable efficacy and potential risk. To
dismiss this warning out of hand is dangerous and unprofessional.
***************************************************
Janie, could you please point me to where Tom says this? I just looked up
Domperidone in the 2004 edition of Meds & Mothers' Milk, (p259-260) and among
a heap of other things, he says, "It is also known to produce significant
increases in prolactin levels and has proven useful as a galactogogue. He then
goes on to cite the study by da Silva, rates the drug as a Lactation Risk
Category L1, and then says under pediatric concerns: None reported. Considered
the ideal galactogogue."
So I'm a bit puzzled as to your statement. Of course, it is always possible
that I missed something somewhere along the line.
Could you please let me know where to find your information? It's really
important that we have, as you say, all our ducks in a row on this issue.
Jan Barger, RN, MA, IBCLC
Wheaton IL
www.lactationeducationconsultants.com
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|